Document ID: chunk:federal_register_of_legislation:F2025C00124:front:0:p2
Version: federal_register_of_legislation:F2025C00124
Segment Type: other
Provision Reference: 
Character Range: 2799–6015

Prescription circumstances—authority required procedures
18 When medication chart prescriptions not to be written
19 Prescriptions not to direct repeated supplies for visitors to Australia
20 Maximum quantity or number of units (Act s 85A(2)(a))
21 Maximum number of repeats (Act s 85A(2)(b))
22 No variation of application of determination of maximum number of repeats or maximum number or quantity of units—HSD pharmaceutical benefits that have CAR drugs
23 Records to be kept—prescriptions for HSD pharmaceutical benefits that have eculizumab for the treatment of atypical haemolytic uraemic syndrome
Division 3—Supplying HSD pharmaceutical benefits
24 Special patient contribution for certain HSD pharmaceutical benefits
25 Conditions for approved pharmacists
26 Supplies need not be directly to persons
27 Repeated supplies of pharmaceutical benefits
Part 3—Payment for special arrangement supplies of HSD pharmaceutical benefits
Division 1—Supplies by approved hospital authorities for public hospitals
28 Rates of payment for approved hospital authorities for public hospitals (Act s 99(4))
29 Dispensed price for approved hospital authorities for public hospitals
Division 2—Supplies by other approved suppliers
30 Entitlement to, and amount of, payment for approved pharmacists and approved medical practitioners
30A Paragraph 99(3)(b) of the Act does not apply to certain HSD pharmaceutical benefits
31 Rates of payment for approved hospital authorities for private hospitals (Act s 99(4))
32 Dispensed price for approved suppliers other than approved hospital authorities for public hospitals
33 Mark‑up for ready‑prepared pharmaceutical benefits
34 Dispensing fee
Part 3A—Supply to CTG registered patients by CTG suppliers
34A Application of this Part
34B Application of the CTG Special Arrangement—co‑payment and payment etc.
Part 4—Claims for payment for special arrangement supplies of HSD pharmaceutical benefits
35 Rules for providing information about supplies—definition of under co‑payment data
35A Claim for payment if an eligible patient is a CTG registered patient
Part 5—Miscellaneous
36 Compliance and audit arrangements
37 Value for safety net purposes for supplies
Part 6—Application, saving and transitional provisions
Division 1—Provisions relating to this instrument as made
38 HSD hospital authorities
Division 2—Provisions relating to the National Health Legislation Amendment (Opioid Dependence Treatment and Maximum Dispensed Quantities) Instrument 2023
39 Purpose of this Division
40 Definitions
41 Definition of special arrangement supply
42 Prescriptions directing supply for dispensing over time
43 Prescriptions directing supply of buprenorphine for injection
44 Prescriptions directing supply of methadone
45 First supply on or after 1 July 2023 deemed to be supply on first presentation
46 Supply on first presentation of prescription (Regulations s 44)
47 Repeat authorisations (Regulations s 52)
48 Prescriptions written in electronic form—additional procedures for giving information (Claims Rules s 7) and keeping documents
49 Information to be given using Claims Transmission System (Claims Rules Sch 1)
50 Pre‑commencement benefits
Division 3—Provisions relating to the